Friess Associates’s Gilead Sciences GILD Stock Holding History

Friess Associates’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-147,635	Closed	-$13.6M	–	149
2016 Q1	$13.6M	Buy	147,635 +190	+0.1%	+$17.1K	1.36%	34
2015 Q4	$14.9M	Sell	147,445 -2,860	-2%	-$298K	1.39%	37
2015 Q3	$14.8M	Sell	150,305 -50,200	-25%	-$5.58M	1.37%	35
2015 Q2	$23.5M	Buy	200,505 +144,825	+260%	+$15.8M	1.96%	5
2015 Q1	$5.46M	Buy	55,680 +10,680	+24%	+$1.08M	0.44%	73
2014 Q4	$4.24M	Buy	+45,000	New	+$4.65M	0.34%	77
2014 Q3	–	Sell	-98,380	Closed	-$8.16M	–	151
2014 Q2	$8.16M	Buy	+98,380	New	+$7.66M	0.66%	61
2014 Q1	–	Sell	-153,575	Closed	-$11.5M	–	157
2013 Q4	$11.5M	Sell	153,575 -6,650	-4%	-$463K	0.87%	48
2013 Q3	$10.1M	Buy	+160,225	New	+$9.58M	0.8%	50

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Friess Associates's GILD Position: Q2 2016 in Review

Friess Associates sold out of Gilead Sciences (GILD) in Q2 2016, closing a stake of 147,635 shares — an estimated $13.6M sold.

Friess Associates first reported a position in GILD in Q3 2013 and held it in 9 quarters. The position peaked at $23.5M in Q2 2015. 1,596 funds tracked by Wall St. Rank hold GILD as of Q2 2016.

Friess Associates reported no remaining Gilead Sciences position as of Q2 2016 after selling out during the quarter.
Friess Associates sold 147,635 Gilead Sciences shares in Q2 2016, an estimated $13.6M.
Friess Associates first reported a position in Gilead Sciences in Q3 2013 and held it in 9 quarters.
Friess Associates's Gilead Sciences position peaked at $23.5M in Q2 2015.
1,596 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2016.

Based on Friess Associates's 13F filing for Q2 2016, filed 12 Aug 2016.